Today, we'll be using the hashtag: #livesc19 for all content.
#livesc19 We'll kick off by looking at what went well and what we can do better together, accompanied by a global update on #COVID19. A focus on the science used to fight the pandemic and the successes/difficulties we had throughout the world. @DrMCecconi@msh_manu@strachanjamie
130,000 healthcare professionals united within @ESICM in a joint approach to #COVID19 across the world. We have enormous challenges ahead. We are better together. #livesc19
"A ventilator is not an ICU bed - an ICU bed is a team of healthcare professionals working together." @DrMCecconi#livesc19
@WHO expert Dr Ann Lindstrand works in immunisation and updates us on #COVID19 Over 163 million cases worldwide and >3.3 Million Deaths austerely frames the topic... #FOAMed#FOAMcc#livesc19
"The science has been extraordinary" - many very safe vaccines rolled out in their billions.... #livesc19 - we have a lot of work yet to do... #COVID19 - the key is collaboration. The green map below needs to be a homogenous colour! @DrMCecconi
Huge distribution of vaccines across the world #COVID19 but 10 countries have administered 76% of all doses. "We are worried about the vaccine race" - of individual countries - it needs to be a global approach #livesc19
95% of member states (of @WHO) have commenced vaccination programmes - but the inequity is CLEAR - 16.5% of doses administered in countries that represent almost HALF of the world's population #livesc19#COVID19
20% vaccine coverage in a country is a critical number - only Bhutan/Mongolia (of LMIC/LIC's) have achieved this #livesc19
Vaccine Rollout Challenges in #COVID19#livesc19 - funding amongst serious problems.... This is COMPLEX work with multiple vaccines. Majority of countries use multiple vaccine types - this adds to coaching, admin and logistical requirements.
'At risk' age shift seen now, in Germany for example. Younger people more at risk of serious #COVID19 complications. Disruption of vaccine rollout is serious. #livesc19
Fascinating insights - general vaccine programmes (measles etc) have slowed down or been POSTPONED due to #COVID19 vaccine prioritisation:
80-90% of research can be considered 'wasteful'.... this is seriously problematic. "Random drugs to small numbers of people outside RCTs etc...." @msh_manu#livesc19
Lockdowns changed the trajectory of the pandemic. The UK learned from Italian lessons. #livesc19#covid19
We know that there is a clear COVID infective pathway in the body now - it's cytotoxic to the cell and *can* lead to immune dysregulation: @msh_manu#livesc19
There are more asymptomatic and mild infections versus hospital admissions/serious disease. We know the general trajectory now. #livesc19#covid19
We are trying to explore #COVID19 in the context of insufficient knowledge. We needed to embrace uncertainty and study it. We need to focus on things that assist BEDSIDE management. #livesc19
There is a serious shift in study numbers and participants - representing tremendous effort from all involved #livesc19#covid19@msh_manu
But we need to look at the mechanisms of dysregulation and injury in #COVID19: severe endothelial injury, vascular thrombosis and *new vessel growth* - these are multitudes greater than ARDS #livesc19
Severe lung perfusion abnormalities in #COVID19 predict (to a degree) an increased risk of ICU and IMV. #livesc19#foamed#foamcc
The lungs of sick H1N1 patients are heavier than #COVID19 lungs #livesc19
Can we use ROX (pulse ox/FiO2 ratio) to dictate therapies in #COVID19? #livesc19
Helmet-delivered NIV was associated with less intubations in #COVID19#livesc19
Dr Piquilloud kicks off a session on COVID ventilation - she highlights what our considerations should be: #livesc19#foamed#foamcc
ARDS IS HETEROGENEOUS! Individualisation of settings is important. Focal v non-focal aspects (many misclassified) on CT/CXR can dictate treatments/strategies? #covid19#livesc19
#COVID19 ARDS is a **very** heterogeneous syndrome. PEEP is very individual. #livesc19
Aforementioned Type L patients might suit PEEP 8-10cmH20 and Type H might suit higher PEEPs? This still needs tested prospectively. #foamed#foamcc#livesc19
How were patients ventilated in 2020 (with #COVID19?) - 14075 patients over 26 studies:
What about ARDS rescue therapies in #COVID19? "Proning" appears to work and is safe. It improves oxygenation. #livesc19
In real life - proning was used a lot, followed by pulmonary vasodilators and then ECMO in a smaller amount... #livesc19#foamcc#foamed
Some serious discussions around CPAP/NIV in deteriorating #COVID19 patients! Best practice is still suggested to perform such NIV in an HDU/ICU setting - but resources may dictate otherwise... *discuss!* #LIVESC19
A potential blindspot is that a lot of our very sick are cared for (expertly) outside an ICU setting, utilising CPAP/NIV - and this is often outside the data capture of ICM trials (and ICNARC in the UK) that frame this into useful information. @iceman_ex@avkwong@Wilkinsonjonny
Loss of radial function and VA uncoupling seen in the right heart in #COVID19 - this is unlike the 'ARDS right heart' @susannaprice
Fascinating - 141 countries, 6 countries, 80% reported a reduction of STEMI presentations during pandemic - and many presenting after the optimal treatment window. Reasons: degree of lockdown, levels of COVID admitted to hospital, restructure of cardiology units. #livesc19
Are the components of #COVID19 within ICU that much different from more traditional critical illnesses? @ElieAzoulay5#livesc19
Dr. Herridge delves into the post-COVID19 conditions. #LIVESC19
High ICU mortality (55%) in Brazil and high admissions (39%) - "COVID is a different disease in different healthcare and social constructs" #livesc19
In intubated patients post-COVID, they have (obviously - but some surprising) different outcomes versus non-intubated patients.... #livesc19 MANY people are re-hospitalised. "Return to normal" is challenging +++ (medical, psychological, financial)
This study made me think about how we deal with things that matter to the survivor patients - from hair loss to sleep difficulties. #livesc19
ENORMOUS impacts on delirium, and one might hypothesise, long-term cognitive function. The battle within polypharmacy is very real.
*Unknown* long term trajectories in COVID19 - a multi-system and complex problem. #livesc19 - can we learn lessons from our ARDS patients? Yes.
"It is very difficult to distinguish covid pneumonia from other pneumonia" We need excellent antimicrobial stewardship. #LIVESC19 Two "ifs and whens" to start abx -->
Co-infection with bacteria at ICU admission stage is VERY difficult to ascertain. But... 28% (limited data) COVID patients had co-existing infection. Look at the % of patients on broad spectrum abx with COVID-19! #livesc19 90% of ICU patients and 72% of hospital pts.
Final thoughts of abx use are common throughout ICU presentations - but some data considerations here - high risk of VA-LRTI after 1 week ICU stay as well as low rate of co-infections at ICU admission. #LIVESC19
Prof. Garyphalia Poulakou is taking us through living reviews and metanalysis of bacterial infections in COVID-19 patients. She highlights the overlapping clinical features of COVID-19 and bacterial pneumonia.
Great insights into how we can predict superinfections in #COVID19 patients. We can all reflect on these issues in ICU #livesc19#foamed#foamcc
How to investigate the COVID-19 patient with suspected co-infection --> #livesc19
β’ β’ β’
Missing some Tweet in this thread? You can try to
force a refresh
What were the most impactful non-COVID papers over the past 2 years? Let's delve in and take a look. #SOA21
Finally an opportunity to not talk about COVID! #SOA21
TOMAHAWK - immediate vs delayed/selective angio. 3 years to conduct the trial in 31 ICUs. 554 patients. 'Worse' survival in immediate angiograph? Not SS, but close... #SOA21
We've looked at bats for a long time.... #SOA21 They have strong interferon responses, but not strong inflammation....
So what happens instead? #SOA21 They will tolerate high levels of viraemia with little symptoms. Bats are old... 65million years ago - they appeared at the end of the dinosaurs! They are far longer lived that other mammals. Senescence is late - more towards end of life.
Organophosphate poisoning, toxicology, dengue, snake bites and malaria.... sure what could go wrong? #SOA21@ICS_updates Drs. Chacko, Yacoub, Bhaumik and Dondorp tell us more.... π§΅ππ
Biomarker guided abx treatments in sepsis. We catch up with Drs/Profs: Paul Dark, Stacy Todd, Enitan Carrol, Jonathan Sandoe and Matthew Stevenson on this large area of research @ICS_updates#SOA21
So, do biomarkers have any utility in guiding abx use in sepsis? We can measure, usually, these ones fairly easily: #SOA21
In around 2014, commissioned review in PCT. Seemed to suggest a shorter duration in abx use when PCT used.... tenuous data though. #SOA21 Low quality. Little evidence from UK... how does this fit into NHS practice in the realms of stewardship?
There's been a lot that's gone on over the past few years that's exposed the well known 'darker' side of social media. Traditional paradigms of knowledge dissemination have changed (if not disappeared). Much higher tech-savy population. #SOA21
This has democratised the discussion space to an extent. It allows for *anybody* (lit. anybody) to get involved. #SOA21
Is COVID-19 hyperinflammation, or a cytokine storm in a teacup? @DrPujaMehta1 's fab talk from #SOA21 today!
Main Q = "Hyperinflation contributing to worse outcomes for some patients with COVID-19" - clinical similarities to sHLH seen. Viruses are the most common trigger of sHLH. Early reports from China suggested cytokine profile was similar to sHLH in terms of COVID severity. #SOA21
We now know some things work and some things don't.... in certain populations. #SOA21